- Home
- MGNI vs TVTX Comparison
MGNI vs TVTX Comparison
Compare MGNI & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNI
- TVTX
- Stock Information
- Founded
- MGNI 2007
- TVTX 2008
- Country
- MGNI United States
- TVTX United States
- Employees
- MGNI N/A
- TVTX N/A
- Industry
- MGNI Computer Software: Programming Data Processing
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- MGNI Technology
- TVTX Health Care
- Exchange
- MGNI Nasdaq
- TVTX Nasdaq
- Market Cap
- MGNI 1.8B
- TVTX 1.9B
- IPO Year
- MGNI N/A
- TVTX N/A
- Fundamental
- Price
- MGNI $11.41
- TVTX $17.92
- Analyst Decision
- MGNI Strong Buy
- TVTX Strong Buy
- Analyst Count
- MGNI 14
- TVTX 13
- Target Price
- MGNI $19.25
- TVTX $33.17
- AVG Volume (30 Days)
- MGNI 2.7M
- TVTX 1.6M
- Earning Date
- MGNI 05-07-2025
- TVTX 05-05-2025
- Dividend Yield
- MGNI N/A
- TVTX N/A
- EPS Growth
- MGNI N/A
- TVTX N/A
- EPS
- MGNI 0.16
- TVTX N/A
- Revenue
- MGNI $668,170,000.00
- TVTX $233,175,000.00
- Revenue This Year
- MGNI $2.23
- TVTX $72.95
- Revenue Next Year
- MGNI $10.93
- TVTX $53.84
- P/E Ratio
- MGNI $71.09
- TVTX N/A
- Revenue Growth
- MGNI 7.82
- TVTX 60.55
- 52 Week Low
- MGNI $8.38
- TVTX $5.12
- 52 Week High
- MGNI $21.29
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- MGNI 29.40
- TVTX 36.88
- Support Level
- MGNI $12.93
- TVTX $20.29
- Resistance Level
- MGNI $13.71
- TVTX $20.98
- Average True Range (ATR)
- MGNI 0.71
- TVTX 0.96
- MACD
- MGNI -0.01
- TVTX -0.10
- Stochastic Oscillator
- MGNI 19.30
- TVTX 11.94
About MGNI Magnite Inc.
Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.